| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| STAT3 Transcription Factor | 15 | 2026 | 226 | 2.540 |
Why?
|
| Lung Diseases, Interstitial | 8 | 2023 | 164 | 1.440 |
Why?
|
| Arthritis, Juvenile | 4 | 2026 | 45 | 1.400 |
Why?
|
| Lung Diseases | 6 | 2026 | 397 | 1.310 |
Why?
|
| Gain of Function Mutation | 12 | 2026 | 114 | 1.250 |
Why?
|
| Autoimmune Diseases | 7 | 2022 | 260 | 1.120 |
Why?
|
| Systemic Inflammatory Response Syndrome | 10 | 2025 | 208 | 1.040 |
Why?
|
| Granulomatosis with Polyangiitis | 4 | 2022 | 39 | 0.940 |
Why?
|
| Rheumatic Diseases | 3 | 2026 | 77 | 0.940 |
Why?
|
| Churg-Strauss Syndrome | 3 | 2022 | 20 | 0.910 |
Why?
|
| Rheumatology | 3 | 2023 | 129 | 0.870 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2024 | 585 | 0.690 |
Why?
|
| Immunologic Deficiency Syndromes | 6 | 2026 | 211 | 0.670 |
Why?
|
| Immune System Diseases | 4 | 2026 | 55 | 0.650 |
Why?
|
| Job Syndrome | 2 | 2020 | 17 | 0.610 |
Why?
|
| Connective Tissue Diseases | 1 | 2019 | 32 | 0.600 |
Why?
|
| Pulmonary Medicine | 1 | 2019 | 33 | 0.590 |
Why?
|
| Caspases | 1 | 2019 | 152 | 0.560 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 3 | 2022 | 27 | 0.510 |
Why?
|
| Child | 35 | 2026 | 26194 | 0.480 |
Why?
|
| Mutation | 12 | 2026 | 6062 | 0.450 |
Why?
|
| Adult Stem Cells | 1 | 2015 | 50 | 0.440 |
Why?
|
| Humans | 64 | 2026 | 130204 | 0.440 |
Why?
|
| Typhus, Endemic Flea-Borne | 2 | 2025 | 28 | 0.430 |
Why?
|
| Inflammation | 4 | 2024 | 1479 | 0.420 |
Why?
|
| Rheumatic Fever | 1 | 2014 | 20 | 0.410 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2026 | 352 | 0.400 |
Why?
|
| T-Lymphocytes, Regulatory | 4 | 2024 | 236 | 0.380 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2014 | 78 | 0.380 |
Why?
|
| Janus Kinases | 2 | 2026 | 36 | 0.370 |
Why?
|
| Intestinal Diseases | 2 | 2026 | 67 | 0.370 |
Why?
|
| Child, Preschool | 19 | 2026 | 15015 | 0.360 |
Why?
|
| Musculoskeletal Diseases | 2 | 2023 | 56 | 0.360 |
Why?
|
| Hematologic Neoplasms | 1 | 2015 | 314 | 0.350 |
Why?
|
| Antirheumatic Agents | 2 | 2023 | 121 | 0.330 |
Why?
|
| Arthritis | 2 | 2023 | 82 | 0.320 |
Why?
|
| Genetic Testing | 4 | 2026 | 1104 | 0.320 |
Why?
|
| Dendritic Cells | 2 | 2024 | 436 | 0.310 |
Why?
|
| Female | 35 | 2026 | 70342 | 0.280 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 2 | 2022 | 159 | 0.270 |
Why?
|
| Male | 30 | 2026 | 64425 | 0.270 |
Why?
|
| Kidney Diseases | 2 | 2023 | 472 | 0.270 |
Why?
|
| Delphi Technique | 1 | 2019 | 278 | 0.270 |
Why?
|
| Alleles | 4 | 2026 | 1674 | 0.260 |
Why?
|
| Flow Cytometry | 4 | 2026 | 765 | 0.260 |
Why?
|
| Immunosuppressive Agents | 3 | 2026 | 655 | 0.260 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2026 | 239 | 0.250 |
Why?
|
| Syndrome | 6 | 2026 | 1156 | 0.250 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2021 | 215 | 0.250 |
Why?
|
| Inflammasomes | 2 | 2019 | 153 | 0.250 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2024 | 228 | 0.250 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 565 | 0.240 |
Why?
|
| Rare Diseases | 1 | 2018 | 205 | 0.240 |
Why?
|
| Th17 Cells | 2 | 2024 | 97 | 0.240 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2022 | 460 | 0.240 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2026 | 31 | 0.240 |
Why?
|
| Polyarteritis Nodosa | 1 | 2025 | 11 | 0.230 |
Why?
|
| Adenosine Deaminase | 1 | 2025 | 89 | 0.230 |
Why?
|
| Coatomer Protein | 2 | 2023 | 28 | 0.220 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2025 | 107 | 0.220 |
Why?
|
| Adolescent | 16 | 2026 | 20816 | 0.220 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2022 | 684 | 0.220 |
Why?
|
| Cytokines | 4 | 2026 | 1333 | 0.220 |
Why?
|
| Lung | 3 | 2023 | 1532 | 0.220 |
Why?
|
| Serpins | 2 | 2004 | 34 | 0.210 |
Why?
|
| Penetrance | 1 | 2025 | 108 | 0.210 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2026 | 125 | 0.210 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2025 | 287 | 0.210 |
Why?
|
| Immunoglobulins | 1 | 2024 | 153 | 0.210 |
Why?
|
| Mosaicism | 1 | 2026 | 247 | 0.200 |
Why?
|
| Adult | 13 | 2026 | 31035 | 0.200 |
Why?
|
| Neurotransmitter Agents | 1 | 2024 | 135 | 0.200 |
Why?
|
| Killer Cells, Natural | 2 | 2017 | 351 | 0.200 |
Why?
|
| Renal Insufficiency | 1 | 2026 | 257 | 0.200 |
Why?
|
| Interleukin-17 | 1 | 2024 | 125 | 0.200 |
Why?
|
| Diagnosis, Differential | 5 | 2026 | 1875 | 0.190 |
Why?
|
| Leukemia, Large Granular Lymphocytic | 1 | 2022 | 1 | 0.190 |
Why?
|
| Membrane Proteins | 2 | 2025 | 1589 | 0.190 |
Why?
|
| Immunologic Memory | 2 | 2004 | 194 | 0.190 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 1690 | 0.190 |
Why?
|
| Phagocytosis | 1 | 2024 | 190 | 0.190 |
Why?
|
| Cadherins | 1 | 2024 | 182 | 0.190 |
Why?
|
| Lymphadenopathy | 1 | 2023 | 31 | 0.190 |
Why?
|
| Physicians | 1 | 2019 | 626 | 0.190 |
Why?
|
| Signal Transduction | 3 | 2026 | 4646 | 0.180 |
Why?
|
| Glomerulonephritis | 1 | 2023 | 75 | 0.180 |
Why?
|
| Synaptic Transmission | 1 | 2024 | 300 | 0.180 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2025 | 203 | 0.180 |
Why?
|
| Animals | 14 | 2026 | 33676 | 0.180 |
Why?
|
| Myositis | 1 | 2022 | 84 | 0.170 |
Why?
|
| Autoimmunity | 4 | 2024 | 175 | 0.170 |
Why?
|
| Hematuria | 1 | 2022 | 48 | 0.170 |
Why?
|
| Hemoptysis | 1 | 2021 | 22 | 0.170 |
Why?
|
| Hereditary Autoinflammatory Diseases | 1 | 2021 | 11 | 0.170 |
Why?
|
| Cohort Studies | 6 | 2026 | 5047 | 0.170 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2021 | 22 | 0.170 |
Why?
|
| Hemorrhage | 2 | 2023 | 485 | 0.170 |
Why?
|
| Sweet Syndrome | 1 | 2021 | 10 | 0.170 |
Why?
|
| Shock | 1 | 2022 | 96 | 0.170 |
Why?
|
| Disease Models, Animal | 3 | 2024 | 4642 | 0.170 |
Why?
|
| Synapses | 1 | 2024 | 428 | 0.160 |
Why?
|
| Lipodystrophy | 1 | 2021 | 37 | 0.160 |
Why?
|
| Dyspnea | 1 | 2022 | 159 | 0.160 |
Why?
|
| Kidney Transplantation | 1 | 2026 | 552 | 0.160 |
Why?
|
| Patient Care Team | 1 | 2025 | 558 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2021 | 137 | 0.160 |
Why?
|
| STAT1 Transcription Factor | 2 | 2018 | 80 | 0.160 |
Why?
|
| Cytokine Receptor gp130 | 1 | 2020 | 12 | 0.160 |
Why?
|
| Cough | 1 | 2021 | 97 | 0.160 |
Why?
|
| Pyrazoles | 2 | 2020 | 350 | 0.160 |
Why?
|
| Autoimmune Hypophysitis | 1 | 2020 | 5 | 0.160 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2021 | 66 | 0.160 |
Why?
|
| Acyl-CoA Oxidase | 1 | 2020 | 10 | 0.160 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 349 | 0.160 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2020 | 29 | 0.160 |
Why?
|
| Infliximab | 1 | 2020 | 61 | 0.160 |
Why?
|
| Macrophages | 1 | 2024 | 660 | 0.150 |
Why?
|
| Monocytes | 1 | 2021 | 335 | 0.150 |
Why?
|
| Genes, Dominant | 1 | 2020 | 242 | 0.150 |
Why?
|
| Immunization | 1 | 2021 | 269 | 0.150 |
Why?
|
| Infant | 10 | 2026 | 13298 | 0.150 |
Why?
|
| Skin Diseases | 1 | 2021 | 142 | 0.150 |
Why?
|
| Data Collection | 1 | 2021 | 370 | 0.150 |
Why?
|
| Nerve Degeneration | 1 | 2020 | 128 | 0.150 |
Why?
|
| Pyroptosis | 1 | 2019 | 35 | 0.140 |
Why?
|
| Contracture | 1 | 2019 | 26 | 0.140 |
Why?
|
| Organ Transplantation | 1 | 2021 | 170 | 0.140 |
Why?
|
| Cell Death | 1 | 2019 | 226 | 0.140 |
Why?
|
| Facies | 1 | 2019 | 157 | 0.140 |
Why?
|
| Pneumonia | 1 | 2022 | 340 | 0.140 |
Why?
|
| Nonsense Mediated mRNA Decay | 1 | 2018 | 37 | 0.130 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2026 | 888 | 0.130 |
Why?
|
| Neuroglia | 1 | 2020 | 216 | 0.130 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2017 | 42 | 0.130 |
Why?
|
| Urticaria | 1 | 2017 | 19 | 0.130 |
Why?
|
| Young Adult | 6 | 2026 | 10000 | 0.130 |
Why?
|
| Growth Disorders | 1 | 2019 | 181 | 0.130 |
Why?
|
| Azathioprine | 1 | 2017 | 36 | 0.130 |
Why?
|
| Molecular Chaperones | 1 | 2018 | 172 | 0.130 |
Why?
|
| Registries | 3 | 2026 | 1608 | 0.130 |
Why?
|
| Crohn Disease | 1 | 2020 | 290 | 0.130 |
Why?
|
| Axons | 1 | 2020 | 382 | 0.130 |
Why?
|
| Skin Transplantation | 1 | 2006 | 56 | 0.120 |
Why?
|
| Toll-Like Receptors | 1 | 2006 | 83 | 0.120 |
Why?
|
| Calcium-Binding Proteins | 1 | 2017 | 322 | 0.120 |
Why?
|
| Neutropenia | 1 | 2017 | 209 | 0.120 |
Why?
|
| Microcephaly | 1 | 2019 | 346 | 0.120 |
Why?
|
| Hematopoiesis | 1 | 2017 | 213 | 0.120 |
Why?
|
| Treatment Outcome | 4 | 2026 | 12824 | 0.120 |
Why?
|
| Immune Tolerance | 1 | 2006 | 150 | 0.120 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2026 | 637 | 0.110 |
Why?
|
| Phosphorylation | 2 | 2015 | 1570 | 0.110 |
Why?
|
| Sepsis | 1 | 2019 | 494 | 0.110 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2004 | 5 | 0.110 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 263 | 0.110 |
Why?
|
| Mice | 9 | 2024 | 18173 | 0.110 |
Why?
|
| Cell Differentiation | 3 | 2021 | 1907 | 0.100 |
Why?
|
| Dermatomyositis | 1 | 2014 | 28 | 0.100 |
Why?
|
| Serine Endopeptidases | 1 | 2004 | 197 | 0.100 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2017 | 542 | 0.100 |
Why?
|
| Ehlers-Danlos Syndrome | 1 | 2014 | 52 | 0.100 |
Why?
|
| Aging | 1 | 2020 | 1238 | 0.100 |
Why?
|
| Arthritis, Infectious | 1 | 2014 | 65 | 0.100 |
Why?
|
| Abnormalities, Multiple | 1 | 2019 | 964 | 0.100 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2017 | 324 | 0.100 |
Why?
|
| Vaccination | 3 | 2023 | 1054 | 0.090 |
Why?
|
| Lymphocyte Activation | 1 | 2015 | 631 | 0.090 |
Why?
|
| Graft Rejection | 1 | 2006 | 556 | 0.090 |
Why?
|
| Myocarditis | 1 | 2014 | 129 | 0.090 |
Why?
|
| Artemisinins | 1 | 2002 | 8 | 0.090 |
Why?
|
| Interferon-gamma | 1 | 2015 | 543 | 0.090 |
Why?
|
| Transferrin | 1 | 2002 | 46 | 0.090 |
Why?
|
| Sesquiterpenes | 1 | 2002 | 26 | 0.090 |
Why?
|
| Carcinoma, Small Cell | 1 | 2002 | 37 | 0.090 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2002 | 100 | 0.090 |
Why?
|
| Intellectual Disability | 1 | 2019 | 1086 | 0.090 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 2 | 2022 | 40 | 0.090 |
Why?
|
| Microscopic Polyangiitis | 2 | 2021 | 14 | 0.080 |
Why?
|
| Streptococcal Infections | 1 | 2014 | 254 | 0.080 |
Why?
|
| Loss of Function Mutation | 2 | 2024 | 169 | 0.080 |
Why?
|
| Genome, Human | 1 | 2018 | 1318 | 0.080 |
Why?
|
| HEK293 Cells | 2 | 2026 | 800 | 0.080 |
Why?
|
| Drosophila | 2 | 2020 | 723 | 0.080 |
Why?
|
| Acute Disease | 1 | 2014 | 1153 | 0.080 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2014 | 468 | 0.080 |
Why?
|
| Homeostasis | 1 | 2004 | 712 | 0.080 |
Why?
|
| Up-Regulation | 3 | 2020 | 823 | 0.080 |
Why?
|
| Pedigree | 2 | 2026 | 1669 | 0.080 |
Why?
|
| Heart Transplantation | 1 | 2006 | 839 | 0.080 |
Why?
|
| Retrospective Studies | 6 | 2023 | 17577 | 0.070 |
Why?
|
| Mice, Knockout | 3 | 2024 | 3812 | 0.070 |
Why?
|
| Exome | 2 | 2018 | 1061 | 0.070 |
Why?
|
| Disease Management | 2 | 2025 | 554 | 0.070 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2018 | 136 | 0.070 |
Why?
|
| Nuclear Proteins | 1 | 2004 | 1209 | 0.070 |
Why?
|
| Hemodynamics | 2 | 2022 | 810 | 0.070 |
Why?
|
| Piperidines | 2 | 2021 | 221 | 0.070 |
Why?
|
| Cells, Cultured | 2 | 2026 | 2885 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 3406 | 0.060 |
Why?
|
| Immunophenotyping | 2 | 2018 | 332 | 0.060 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2022 | 500 | 0.060 |
Why?
|
| Models, Animal | 1 | 2018 | 448 | 0.060 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 310 | 0.060 |
Why?
|
| Biomarkers | 1 | 2026 | 3358 | 0.060 |
Why?
|
| Pyrimidines | 2 | 2021 | 448 | 0.060 |
Why?
|
| Autoantibodies | 2 | 2021 | 435 | 0.060 |
Why?
|
| Agammaglobulinemia | 1 | 2025 | 42 | 0.060 |
Why?
|
| Scrub Typhus | 1 | 2025 | 6 | 0.060 |
Why?
|
| United States | 3 | 2023 | 11959 | 0.050 |
Why?
|
| Health Care Costs | 1 | 2018 | 407 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2019 | 1439 | 0.050 |
Why?
|
| Interleukin-10 | 1 | 2026 | 188 | 0.050 |
Why?
|
| c-Mer Tyrosine Kinase | 1 | 2024 | 12 | 0.050 |
Why?
|
| Phagocytes | 1 | 2024 | 25 | 0.050 |
Why?
|
| Terpenes | 1 | 2024 | 30 | 0.050 |
Why?
|
| ROC Curve | 1 | 2026 | 609 | 0.050 |
Why?
|
| Myeloid Cells | 1 | 2024 | 112 | 0.050 |
Why?
|
| Cell Adhesion Molecules | 1 | 2024 | 222 | 0.050 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2022 | 13 | 0.050 |
Why?
|
| Apoptosis | 3 | 2004 | 1826 | 0.050 |
Why?
|
| Hyperplasia | 1 | 2023 | 189 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 1205 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 1547 | 0.040 |
Why?
|
| Middle Aged | 4 | 2025 | 28315 | 0.040 |
Why?
|
| Thrombomodulin | 1 | 2021 | 18 | 0.040 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 55 | 0.040 |
Why?
|
| Neuronal Plasticity | 1 | 2024 | 283 | 0.040 |
Why?
|
| Infant, Newborn | 3 | 2021 | 8622 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 3 | 2015 | 4694 | 0.040 |
Why?
|
| Myeloblastin | 1 | 2021 | 18 | 0.040 |
Why?
|
| Tumor Necrosis Factor alpha-Induced Protein 3 | 1 | 2021 | 9 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2018 | 2548 | 0.040 |
Why?
|
| Receptors, IgG | 1 | 2021 | 59 | 0.040 |
Why?
|
| Peroxidase | 1 | 2021 | 63 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2025 | 920 | 0.040 |
Why?
|
| Potassium | 1 | 2022 | 263 | 0.040 |
Why?
|
| Prednisolone | 1 | 2021 | 73 | 0.040 |
Why?
|
| GPI-Linked Proteins | 1 | 2021 | 109 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2022 | 345 | 0.040 |
Why?
|
| Fibrosis | 1 | 2023 | 420 | 0.040 |
Why?
|
| Platelet Count | 1 | 2021 | 139 | 0.040 |
Why?
|
| Sodium | 1 | 2022 | 280 | 0.040 |
Why?
|
| Methylprednisolone | 1 | 2021 | 94 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2025 | 2076 | 0.040 |
Why?
|
| France | 1 | 2020 | 90 | 0.040 |
Why?
|
| Immunity | 1 | 2021 | 178 | 0.040 |
Why?
|
| Aspirin | 1 | 2021 | 213 | 0.040 |
Why?
|
| Time Factors | 2 | 2022 | 6166 | 0.040 |
Why?
|
| Haploinsufficiency | 1 | 2021 | 265 | 0.040 |
Why?
|
| Phenotype | 2 | 2020 | 4454 | 0.040 |
Why?
|
| Th2 Cells | 1 | 2020 | 188 | 0.040 |
Why?
|
| Genetics, Population | 1 | 2020 | 177 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2021 | 230 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2021 | 290 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 4036 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2021 | 345 | 0.040 |
Why?
|
| Endocrine System Diseases | 1 | 2019 | 42 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2021 | 639 | 0.030 |
Why?
|
| Kinetics | 1 | 2020 | 1087 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2021 | 766 | 0.030 |
Why?
|
| Fever | 1 | 2021 | 312 | 0.030 |
Why?
|
| Unfolded Protein Response | 1 | 2018 | 66 | 0.030 |
Why?
|
| Hematologic Diseases | 1 | 2019 | 82 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2020 | 450 | 0.030 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2024 | 627 | 0.030 |
Why?
|
| Mutant Proteins | 1 | 2018 | 112 | 0.030 |
Why?
|
| Nitriles | 1 | 2018 | 161 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 818 | 0.030 |
Why?
|
| Interferon Type I | 1 | 2018 | 118 | 0.030 |
Why?
|
| CD56 Antigen | 1 | 2017 | 26 | 0.030 |
Why?
|
| Mutation Rate | 1 | 2017 | 68 | 0.030 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2018 | 127 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 448 | 0.030 |
Why?
|
| Interleukin-18 | 1 | 2017 | 75 | 0.030 |
Why?
|
| Recurrence | 1 | 2021 | 1473 | 0.030 |
Why?
|
| K562 Cells | 1 | 2017 | 97 | 0.030 |
Why?
|
| Frameshift Mutation | 1 | 2018 | 198 | 0.030 |
Why?
|
| Biopsy | 1 | 2020 | 1240 | 0.030 |
Why?
|
| Pyrroles | 1 | 2018 | 188 | 0.030 |
Why?
|
| Transplantation, Heterotopic | 1 | 2006 | 15 | 0.030 |
Why?
|
| Withholding Treatment | 1 | 2017 | 76 | 0.030 |
Why?
|
| Multifactorial Inheritance | 1 | 2018 | 174 | 0.030 |
Why?
|
| Epilepsy | 1 | 2024 | 865 | 0.030 |
Why?
|
| Mice, Inbred C3H | 1 | 2006 | 95 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 368 | 0.030 |
Why?
|
| Remission Induction | 1 | 2017 | 305 | 0.030 |
Why?
|
| CD40 Ligand | 1 | 2006 | 65 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2017 | 271 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2020 | 849 | 0.030 |
Why?
|
| Heterozygote | 1 | 2018 | 721 | 0.030 |
Why?
|
| Exons | 1 | 2018 | 759 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2019 | 336 | 0.030 |
Why?
|
| Models, Biological | 1 | 2020 | 1375 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2022 | 2463 | 0.030 |
Why?
|
| Methotrexate | 1 | 2017 | 348 | 0.030 |
Why?
|
| Disease Progression | 1 | 2021 | 2190 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1115 | 0.030 |
Why?
|
| Family | 1 | 2018 | 587 | 0.030 |
Why?
|
| Radiation Chimera | 1 | 2004 | 16 | 0.030 |
Why?
|
| Granzymes | 1 | 2004 | 44 | 0.030 |
Why?
|
| Lymphocytic Choriomeningitis | 1 | 2004 | 12 | 0.030 |
Why?
|
| Lymphocytic choriomeningitis virus | 1 | 2004 | 15 | 0.030 |
Why?
|
| Jurkat Cells | 1 | 2004 | 83 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2006 | 668 | 0.030 |
Why?
|
| Crosses, Genetic | 1 | 2004 | 152 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2004 | 118 | 0.030 |
Why?
|
| Neurons | 1 | 2024 | 1979 | 0.030 |
Why?
|
| STAT5 Transcription Factor | 1 | 2014 | 93 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2006 | 979 | 0.030 |
Why?
|
| Base Sequence | 1 | 2018 | 2730 | 0.030 |
Why?
|
| Interleukin-15 | 1 | 2015 | 104 | 0.030 |
Why?
|
| Rats | 1 | 2020 | 3372 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 610 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 2057 | 0.020 |
Why?
|
| Cell Line | 1 | 2018 | 2553 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 1592 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2004 | 339 | 0.020 |
Why?
|
| Receptors, Transferrin | 1 | 2002 | 11 | 0.020 |
Why?
|
| DNA Fragmentation | 1 | 2002 | 53 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2002 | 83 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2002 | 120 | 0.020 |
Why?
|
| Texas | 1 | 2020 | 3655 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 992 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 1828 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2006 | 977 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 975 | 0.020 |
Why?
|
| Cell Survival | 1 | 2002 | 828 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2017 | 1578 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2004 | 2331 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2006 | 5166 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2002 | 812 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 2323 | 0.010 |
Why?
|